噻嗪类利尿剂存在显著效力差异

2012-05-06 高晓方译 医学论坛网

  英国学者的一项荟萃分析表明,氢氯噻嗪、氯噻酮和苄氟噻嗪在效力方面存在显著差异,这可能解释了标准剂量氢氯噻嗪和氯噻酮的降压效果差异。论文于2012年4月30日在线发表于《高血压》(Hypertension)杂志。   噻嗪类和噻嗪样利尿剂被广泛用于高血压治疗,但近来对氢氯噻嗪和氯噻酮在降压和心血管疾病预防方面的等效性有所质疑。此项研究对3种广泛应用噻嗪类利尿剂(氢氯噻嗪、氯噻酮和苄氟噻嗪)与血

  英国学者的一项荟萃分析表明,氢氯噻嗪、氯噻酮和苄氟噻嗪在效力方面存在显著差异,这可能解释了标准剂量氢氯噻嗪和氯噻酮的降压效果差异。论文于2012年4月30日在线发表于《高血压》(Hypertension)杂志。

  噻嗪类和噻嗪样利尿剂被广泛用于高血压治疗,但近来对氢氯噻嗪和氯噻酮在降压和心血管疾病预防方面的等效性有所质疑。此项研究对3种广泛应用噻嗪类利尿剂(氢氯噻嗪、氯噻酮和苄氟噻嗪)与血压、血钾和尿酸的剂量应答关系特征进行了荟萃分析。研究者检索了Embase、Medline、对照试验荟萃注册和Cochrane中心,并纳入符合预设标准的随机、双盲、平行组安慰剂对照试验。

  结果显示,评估氢氯噻嗪、氯噻酮和苄氟噻嗪的试验分别为26、3和1项,共涉及4683例受试者。噻嗪类对收缩压影响的荟萃回归显示出伴有下述效力序列的对数-线性关系:苄氟噻嗪>氯噻酮>氢氯噻嗪。3种药物预计降低收缩压10 mmHg的估计剂量分别为1.4、8.6和26.4 mg。无证据显示大剂量不同噻嗪类利尿剂在最大限度降低收缩压方面存在差异。舒张压、血钾和尿酸的效力序列与收缩压结果类似。

  链接:

  Meta-Analysis of Dose-Response Relationships for Hydrochlorothiazide, Chlorthalidone, and Bendroflumethiazide on Blood Pressure, Serum Potassium, and Urate



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643215, encodeId=248e1643215cb, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Fri Aug 17 13:18:00 CST 2012, time=2012-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957426, encodeId=e7b4195e4268d, content=<a href='/topic/show?id=c8f14036801' target=_blank style='color:#2F92EE;'>#噻嗪类利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40368, encryptionId=c8f14036801, topicName=噻嗪类利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Thu May 17 16:18:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271915, encodeId=268112e191516, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-08-17 fangcong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643215, encodeId=248e1643215cb, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Fri Aug 17 13:18:00 CST 2012, time=2012-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957426, encodeId=e7b4195e4268d, content=<a href='/topic/show?id=c8f14036801' target=_blank style='color:#2F92EE;'>#噻嗪类利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40368, encryptionId=c8f14036801, topicName=噻嗪类利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Thu May 17 16:18:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271915, encodeId=268112e191516, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643215, encodeId=248e1643215cb, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Fri Aug 17 13:18:00 CST 2012, time=2012-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957426, encodeId=e7b4195e4268d, content=<a href='/topic/show?id=c8f14036801' target=_blank style='color:#2F92EE;'>#噻嗪类利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40368, encryptionId=c8f14036801, topicName=噻嗪类利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/C4Qhy5XHSe503Qbjzc1UtDR83BCv66o6P2XRedX9ohsNGa3uEVicFFk2qkuX5zBSmpicepFySBrwoYknhqMdKmtw/132, createdBy=1aca2500179, createdName=12498d2fm51(暂无昵称), createdTime=Thu May 17 16:18:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271915, encodeId=268112e191516, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]

相关资讯

更换或添加药物或可解决噻嗪类诱导糖尿病

  英国学者的一项研究表明,替换药物或添加阿米洛利可能是预防噻嗪类诱导糖尿病的解决方案。论文于2012年4月9日在线发表于《高血压》(Hypertension)杂志。   高血压指南建议限制噻嗪类利尿剂用量并避免联用β受体阻滞剂,原因在于其可升高糖尿病风险。研究者实施了两项双盲、安慰剂对照、交叉研究。在纳入41例患者的第一项研究中,苄氟噻嗪治疗4周后可检查到2小时口服糖耐量试验时的血糖

更换或添加药物或可解决噻嗪类诱导糖尿病

  英国学者的一项研究表明,替换药物或添加阿米洛利可能是预防噻嗪类诱导糖尿病的解决方案。论文于2012年4月9日在线发表于《高血压》(Hypertension)杂志。   高血压指南建议限制噻嗪类利尿剂用量并避免联用β受体阻滞剂,原因在于其可升高糖尿病风险。研究者实施了两项双盲、安慰剂对照、交叉研究。在纳入41例患者的第一项研究中,苄氟噻嗪治疗4周后可检查到2小时口服糖耐量试验时的血糖